ESLA Q1 2026 Earnings EPS Misses Estimates by Wide Margin as ClinicalStage Biotech Continues RD Spending DTW Q1 2026 Earnings EPS Misses Estimates as Revenue Remains Undisclosed UPBD Q1 2026 Earnings EPS Beats Estimates by 247 UZD Q1 2026 Earnings Strong EPS Beat Drives Modest Stock Gains Catalyst Pharmaceuticals CPRX Q1 2026 Earnings EPS Beat Signals Operational Strength Amid Quiet Revenue Reporting OGI Q1 2026 Earnings Narrowerthanexpected loss signals improving cost discipline